Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://himemix.com/teigaku/model/no/2085
Are you over 18 and want to see adult content?
A complete backup of https://www.babeshows.co.uk/showthread.php?tid=77360
Are you over 18 and want to see adult content?
A complete backup of https://x.yump3.ws/descargar-mp3/sarbe-la-orga
Are you over 18 and want to see adult content?
A complete backup of https://chinaq.tv/great-expectations/
Are you over 18 and want to see adult content?
A complete backup of https://www.darknight.blog/ss2/
Are you over 18 and want to see adult content?
A complete backup of https://www.babeshows.co.uk/forumdisplay.php?fid=25
Are you over 18 and want to see adult content?
Favourite Annotations
Ancaster Toyota: New & Used Toyota Dealership | Ancaster, ON.
Are you over 18 and want to see adult content?
RadLibrary - Diagnostic radiology website. Targeting both professionals and public.
Are you over 18 and want to see adult content?
Ciencias Sociales (Geografia)
Are you over 18 and want to see adult content?
Clipart Kiste - kostenlose animierte Gifs & gratis Cliparts zum kostenlosen Download
Are you over 18 and want to see adult content?
CardCow Vintage Postcards - Old, Antique Post Cards, Photographs & Collectibles
Are you over 18 and want to see adult content?
Text
NEWS & EVENTS
Conference Call to Begin Today at 5:00 PM ET 1Q 2021 Total Revenues of $17.4 million ; +7% vs. 1Q 2020 Received $230.0 million gross proceeds from 2.5% sen WESTLAKE VILLAGE, Calif. , May 11, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercializatio CAREERS - MANNKIND CORPORATION Thrive with MannKind. Our Total Rewards employee benefits package includes a competitive salary and comprehensive benefits, helping you live the life you want. And, every MannKind employee is eligible for one of our bonus plans and our annual equity program, because our success wouldn’t be possible without the dedication of our people.INVESTOR HOME
Computershare. 462 South 4th Street Suite 1600 Louisville, KY 40202 Phone: +1 877 484 5051 ABOUT MANNKIND'S MISSION At MannKind, our Values serve as the foundation of our culture. Inspired by our employees, they embody the spirit and drive of our founder Alfred Mann, and reflect how we aspire to drive our business forward. They define who we are, how we act, and guide our interactions every day—both with each other and the customers weserve.
PIPELINE - MANNKIND CORPORATION MannKind sources critical raw materials from suppliers in the United States and Europe and we remain in close communication with key suppliers to assure a reliable supply of insulin. Our US manufacturing facility is fully operational and we are taking a number of steps to prevent any impact to our supplies. ABOUT MANNKIND CORPORATION'S TEAM Michael Castagna, PharmD Chief Executive Officer. Michael is a dedicated leader who is focused on developing a great team at MannKind. A team whose members all know there’s a difference between just managing and truly living with a condition—and who are driven to develop the products and therapies that can help people take control of their health and experience the best of what life has to APRIL 2021 INVESTOR UPDATE April 2021 investor update Our fourth quarter of 2020 produced exceptional results and I’m proud of our growth to start 2021. We continued to work with United 2021 ANNUAL MEETING OF STOCKHOLDERS Event Details. Title. 2021 Annual Meeting of Stockholders. Date and Time. 05/20/21 8:00 AM PDT. Supporting Materials. Supporting Materials. View Presentation. 1.2 MB.OWNERSHIP PROFILE
The Investor Relations website contains information about MannKind Corporation's business for stockholders, potential investors, andfinancial analysts.
MANNKIND ANNOUNCES PRICING OF $40 MILLION PUBLIC OFFERING MannKind Announces Pricing of $40 Million Public Offering. 12/19/18. PDF Version. WESTLAKE VILLAGE, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) ( MannKind) today announced the pricing of an underwritten public offering of 26,666,667 shares of its common stock and warrants to purchase up to an aggregate ofNEWS & EVENTS
Conference Call to Begin Today at 5:00 PM ET 1Q 2021 Total Revenues of $17.4 million ; +7% vs. 1Q 2020 Received $230.0 million gross proceeds from 2.5% sen WESTLAKE VILLAGE, Calif. , May 11, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercializatio CAREERS - MANNKIND CORPORATION Thrive with MannKind. Our Total Rewards employee benefits package includes a competitive salary and comprehensive benefits, helping you live the life you want. And, every MannKind employee is eligible for one of our bonus plans and our annual equity program, because our success wouldn’t be possible without the dedication of our people.INVESTOR HOME
Computershare. 462 South 4th Street Suite 1600 Louisville, KY 40202 Phone: +1 877 484 5051 ABOUT MANNKIND'S MISSION At MannKind, our Values serve as the foundation of our culture. Inspired by our employees, they embody the spirit and drive of our founder Alfred Mann, and reflect how we aspire to drive our business forward. They define who we are, how we act, and guide our interactions every day—both with each other and the customers weserve.
PIPELINE - MANNKIND CORPORATION MannKind sources critical raw materials from suppliers in the United States and Europe and we remain in close communication with key suppliers to assure a reliable supply of insulin. Our US manufacturing facility is fully operational and we are taking a number of steps to prevent any impact to our supplies. ABOUT MANNKIND CORPORATION'S TEAM Michael Castagna, PharmD Chief Executive Officer. Michael is a dedicated leader who is focused on developing a great team at MannKind. A team whose members all know there’s a difference between just managing and truly living with a condition—and who are driven to develop the products and therapies that can help people take control of their health and experience the best of what life has to APRIL 2021 INVESTOR UPDATE April 2021 investor update Our fourth quarter of 2020 produced exceptional results and I’m proud of our growth to start 2021. We continued to work with United 2021 ANNUAL MEETING OF STOCKHOLDERS Event Details. Title. 2021 Annual Meeting of Stockholders. Date and Time. 05/20/21 8:00 AM PDT. Supporting Materials. Supporting Materials. View Presentation. 1.2 MB.OWNERSHIP PROFILE
The Investor Relations website contains information about MannKind Corporation's business for stockholders, potential investors, andfinancial analysts.
MANNKIND ANNOUNCES PRICING OF $40 MILLION PUBLIC OFFERING MannKind Announces Pricing of $40 Million Public Offering. 12/19/18. PDF Version. WESTLAKE VILLAGE, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) ( MannKind) today announced the pricing of an underwritten public offering of 26,666,667 shares of its common stock and warrants to purchase up to an aggregate of PATIENTS - MANNKIND CORPORATION Afrezza ® (insulin human) Inhalation Powder. Learn about our treatment option for patients with type 1 and type 2 diabetes, utilizing our needle-free, inhaled Technosphere ® Technology. Full Prescribing Information, including BOXED WARNING, Instructions for Use, and Medication Guide can be accessed at afrezza.com.. learn more ABOUT MANNKIND'S MISSION At MannKind, our Values serve as the foundation of our culture. Inspired by our employees, they embody the spirit and drive of our founder Alfred Mann, and reflect how we aspire to drive our business forward. They define who we are, how we act, and guide our interactions every day—both with each other and the customers weserve.
PUBLICATIONS
Med. 2020; 37: 752–759. view publication. Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study. Diabetes Technol. Ther. 2018; 20 (10): 639-647. viewpublication.
CONTACT - MANNKIND CORPORATION With the spread of the coronavirus, many individuals are concerned about access to their medication supply. At this time, MannKind does not anticipate that the supply of its inhalable insulin Afrezza ® (insulin human) Inhalation Powder will be affected by the coronavirus.. We will continue to closely monitor our supply chain for potential impact to the supply of Afrezza. PARTNERING - MANNKIND CORPORATION An ultra rapid-acting, inhaled insulin, Afrezza ® offers glucose management in the moment for adults living with type 1 or type 2 diabetes. Now, we’re working to offer Afrezza ® to more people globally. We currently have partnerships in Brazil and India; for commercial opportunities in other regions, contact bd@mannkindcorp.com. MANNKIND AND THIRONA BIO JOIN FORCES TO EVALUATE POTENTIAL MannKind will conduct formulation and preclinical studies of a new chemical entity owned by Thirona. In addition, MannKind purchased a convertible note issued by Thirona WESTLAKE VILLAGE, Calif. and SAN DIEGO, June 10, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) and Thirona Bio, Inc. today announced that they have entered into a transaction that is intended to advancePATENT NOTICES
Patent Notices. This product may be covered by U.S. Patent No.: Interactive apparatus and method for real-time profiling of inhalation efforts. This product or the process of its manufacture may be covered by U.S. patents, including: Unit dose capsules for use in a dry NOVEMBER 2020 INVESTOR UPDATE November 2020 investor update upcoming milestones connect with us Afrezza Expand AfrezzaAssistSM to improve the patient experience and lower patient costs. Trepostinil Technosphere® (TreT) Partner with United Therapeutics to prepare an FDA submission for TreT, planned MANNKIND ANNOUNCES PRICING OF $40 MILLION PUBLIC OFFERING WESTLAKE VILLAGE, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) (MannKind) today announced the pricing of an underwritten public offering of 26,666,667 shares of its common stock and warrants to purchase up to an aggregate of 26,666,667 shares of its common stock. Each share of common stock is being sold togetherwith a warrant to
PATRICK MCCAULEY JOINS MANNKIND AS CHIEF COMMERCIAL VALENCIA, Calif., July 12, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today announced that Patrick McCauley, J.D., M.B.A., has joined the company as its Chief Commercial Officer with full responsibilities for leading MannKind's commercial operations on a global basis, effective immediately.Mr. McCauley will report directly to Michael MANNKIND CORPORATION Drawing on the legacy of innovator and humanitarian Alfred E. Mann, our team of passionate scientists, researchers, and professionals develops cutting-edge therapeutic products and technologies that help people take control of their health and live—fully humann. PATIENTS - MANNKIND CORPORATION Afrezza ® (insulin human) Inhalation Powder. Learn about our treatment option for patients with type 1 and type 2 diabetes, utilizing our needle-free, inhaled Technosphere ® Technology. Full Prescribing Information, including BOXED WARNING, Instructions for Use, and Medication Guide can be accessed at afrezza.com.. learn moreNEWS & EVENTS
Conference Call to Begin Today at 5:00 PM ET 1Q 2021 Total Revenues of $17.4 million ; +7% vs. 1Q 2020 Received $230.0 million gross proceeds from 2.5% sen WESTLAKE VILLAGE, Calif. , May 11, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercializatio CAREERS - MANNKIND CORPORATION Thrive with MannKind. Our Total Rewards employee benefits package includes a competitive salary and comprehensive benefits, helping you live the life you want. And, every MannKind employee is eligible for one of our bonus plans and our annual equity program, because our success wouldn’t be possible without the dedication of our people.INVESTOR HOME
Computershare. 462 South 4th Street Suite 1600 Louisville, KY 40202 Phone: +1 877 484 5051 PIPELINE - MANNKIND CORPORATIONNON UNION PIPELINE JOBSPLAINS ALL AMERICAN PIPELINE PROJECTS MannKind sources critical raw materials from suppliers in the United States and Europe and we remain in close communication with key suppliers to assure a reliable supply of insulin. Our US manufacturing facility is fully operational and we are taking a number of steps to prevent any impact to our supplies. ABOUT MANNKIND CORPORATION'S TEAM Michael Castagna, PharmD Chief Executive Officer. Michael is a dedicated leader who is focused on developing a great team at MannKind. A team whose members all know there’s a difference between just managing and truly living with a condition—and who are driven to develop the products and therapies that can help people take control of their health and experience the best of what life has to APRIL 2021 INVESTOR UPDATE April 2021 investor update Our fourth quarter of 2020 produced exceptional results and I’m proud of our growth to start 2021. We continued to work with United PARTNERING - MANNKIND CORPORATION An ultra rapid-acting, inhaled insulin, Afrezza ® offers glucose management in the moment for adults living with type 1 or type 2 diabetes. Now, we’re working to offer Afrezza ® to more people globally. We currently have partnerships in Brazil and India; for commercial opportunities in other regions, contact bd@mannkindcorp.com. 2021 ANNUAL MEETING OF STOCKHOLDERS Event Details. Title. 2021 Annual Meeting of Stockholders. Date and Time. 05/20/21 8:00 AM PDT. Supporting Materials. Supporting Materials. View Presentation. 1.2 MB. MANNKIND CORPORATION Drawing on the legacy of innovator and humanitarian Alfred E. Mann, our team of passionate scientists, researchers, and professionals develops cutting-edge therapeutic products and technologies that help people take control of their health and live—fully humann. PATIENTS - MANNKIND CORPORATION Afrezza ® (insulin human) Inhalation Powder. Learn about our treatment option for patients with type 1 and type 2 diabetes, utilizing our needle-free, inhaled Technosphere ® Technology. Full Prescribing Information, including BOXED WARNING, Instructions for Use, and Medication Guide can be accessed at afrezza.com.. learn moreNEWS & EVENTS
Conference Call to Begin Today at 5:00 PM ET 1Q 2021 Total Revenues of $17.4 million ; +7% vs. 1Q 2020 Received $230.0 million gross proceeds from 2.5% sen WESTLAKE VILLAGE, Calif. , May 11, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercializatio CAREERS - MANNKIND CORPORATION Thrive with MannKind. Our Total Rewards employee benefits package includes a competitive salary and comprehensive benefits, helping you live the life you want. And, every MannKind employee is eligible for one of our bonus plans and our annual equity program, because our success wouldn’t be possible without the dedication of our people.INVESTOR HOME
Computershare. 462 South 4th Street Suite 1600 Louisville, KY 40202 Phone: +1 877 484 5051 PIPELINE - MANNKIND CORPORATIONNON UNION PIPELINE JOBSPLAINS ALL AMERICAN PIPELINE PROJECTS MannKind sources critical raw materials from suppliers in the United States and Europe and we remain in close communication with key suppliers to assure a reliable supply of insulin. Our US manufacturing facility is fully operational and we are taking a number of steps to prevent any impact to our supplies. ABOUT MANNKIND CORPORATION'S TEAM Michael Castagna, PharmD Chief Executive Officer. Michael is a dedicated leader who is focused on developing a great team at MannKind. A team whose members all know there’s a difference between just managing and truly living with a condition—and who are driven to develop the products and therapies that can help people take control of their health and experience the best of what life has to APRIL 2021 INVESTOR UPDATE April 2021 investor update Our fourth quarter of 2020 produced exceptional results and I’m proud of our growth to start 2021. We continued to work with United PARTNERING - MANNKIND CORPORATION An ultra rapid-acting, inhaled insulin, Afrezza ® offers glucose management in the moment for adults living with type 1 or type 2 diabetes. Now, we’re working to offer Afrezza ® to more people globally. We currently have partnerships in Brazil and India; for commercial opportunities in other regions, contact bd@mannkindcorp.com. 2021 ANNUAL MEETING OF STOCKHOLDERS Event Details. Title. 2021 Annual Meeting of Stockholders. Date and Time. 05/20/21 8:00 AM PDT. Supporting Materials. Supporting Materials. View Presentation. 1.2 MB. PATIENTS - MANNKIND CORPORATION Afrezza ® (insulin human) Inhalation Powder. Learn about our treatment option for patients with type 1 and type 2 diabetes, utilizing our needle-free, inhaled Technosphere ® Technology. Full Prescribing Information, including BOXED WARNING, Instructions for Use, and Medication Guide can be accessed at afrezza.com.. learn more ABOUT MANNKIND'S MISSION At MannKind, our Values serve as the foundation of our culture. Inspired by our employees, they embody the spirit and drive of our founder Alfred Mann, and reflect how we aspire to drive our business forward. They define who we are, how we act, and guide our interactions every day—both with each other and the customers weserve.
PUBLICATIONS
Med. 2020; 37: 752–759. view publication. Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study. Diabetes Technol. Ther. 2018; 20 (10): 639-647. viewpublication.
CONTACT - MANNKIND CORPORATION With the spread of the coronavirus, many individuals are concerned about access to their medication supply. At this time, MannKind does not anticipate that the supply of its inhalable insulin Afrezza ® (insulin human) Inhalation Powder will be affected by the coronavirus.. We will continue to closely monitor our supply chain for potential impact to the supply of Afrezza.CORONAVIRUS UPDATE
With the spread of the coronavirus, many individuals are concerned about access to their medication supply. At this time, MannKind does not anticipate that the supply of its inhalable insulin Afrezza ® (insulin human) Inhalation Powder will be affected by the coronavirus.. We will continue to closely monitor our supply chain for potential impact to the supply of Afrezza. CORPORATE GOVERNANCE Corporate Governance. The Board of Directors of MannKind Corporation (the “Company”) sets high standards for the Company’s employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and tooversee
ANNUAL REPORTS
MannKind Corporation 30930 Russell Ranch Road, Suite 300 Westlake Village, CA 91362 USA EVENTS & PRESENTATIONS MannKind Corporation First Quarter 2021 Earnings Call. 03/17/21. 1:50PM EDT.
OWNERSHIP PROFILE
The Investor Relations website contains information about MannKind Corporation's business for stockholders, potential investors, andfinancial analysts.
MANNKIND ANNOUNCES PRICING OF $40 MILLION PUBLIC OFFERING MannKind Announces Pricing of $40 Million Public Offering. 12/19/18. PDF Version. WESTLAKE VILLAGE, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) ( MannKind) today announced the pricing of an underwritten public offering of 26,666,667 shares of its common stock and warrants to purchase up to an aggregate of MANNKIND CORPORATION Drawing on the legacy of innovator and humanitarian Alfred E. Mann, our team of passionate scientists, researchers, and professionals develops cutting-edge therapeutic products and technologies that help people take control of their health and live—fully humann. PATIENTS - MANNKIND CORPORATION Afrezza ® (insulin human) Inhalation Powder. Learn about our treatment option for patients with type 1 and type 2 diabetes, utilizing our needle-free, inhaled Technosphere ® Technology. Full Prescribing Information, including BOXED WARNING, Instructions for Use, and Medication Guide can be accessed at afrezza.com.. learn moreNEWS & EVENTS
Conference Call to Begin Today at 5:00 PM ET 1Q 2021 Total Revenues of $17.4 million ; +7% vs. 1Q 2020 Received $230.0 million gross proceeds from 2.5% sen WESTLAKE VILLAGE, Calif. , May 11, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercializatio CAREERS - MANNKIND CORPORATION Thrive with MannKind. Our Total Rewards employee benefits package includes a competitive salary and comprehensive benefits, helping you live the life you want. And, every MannKind employee is eligible for one of our bonus plans and our annual equity program, because our success wouldn’t be possible without the dedication of our people.INVESTOR HOME
Computershare. 462 South 4th Street Suite 1600 Louisville, KY 40202 Phone: +1 877 484 5051 PIPELINE - MANNKIND CORPORATIONNON UNION PIPELINE JOBSPLAINS ALL AMERICAN PIPELINE PROJECTS MannKind sources critical raw materials from suppliers in the United States and Europe and we remain in close communication with key suppliers to assure a reliable supply of insulin. Our US manufacturing facility is fully operational and we are taking a number of steps to prevent any impact to our supplies. ABOUT MANNKIND CORPORATION'S TEAM Michael Castagna, PharmD Chief Executive Officer. Michael is a dedicated leader who is focused on developing a great team at MannKind. A team whose members all know there’s a difference between just managing and truly living with a condition—and who are driven to develop the products and therapies that can help people take control of their health and experience the best of what life has to APRIL 2021 INVESTOR UPDATE April 2021 investor update Our fourth quarter of 2020 produced exceptional results and I’m proud of our growth to start 2021. We continued to work with United PARTNERING - MANNKIND CORPORATION An ultra rapid-acting, inhaled insulin, Afrezza ® offers glucose management in the moment for adults living with type 1 or type 2 diabetes. Now, we’re working to offer Afrezza ® to more people globally. We currently have partnerships in Brazil and India; for commercial opportunities in other regions, contact bd@mannkindcorp.com. 2021 ANNUAL MEETING OF STOCKHOLDERS Event Details. Title. 2021 Annual Meeting of Stockholders. Date and Time. 05/20/21 8:00 AM PDT. Supporting Materials. Supporting Materials. View Presentation. 1.2 MB. MANNKIND CORPORATION Drawing on the legacy of innovator and humanitarian Alfred E. Mann, our team of passionate scientists, researchers, and professionals develops cutting-edge therapeutic products and technologies that help people take control of their health and live—fully humann. PATIENTS - MANNKIND CORPORATION Afrezza ® (insulin human) Inhalation Powder. Learn about our treatment option for patients with type 1 and type 2 diabetes, utilizing our needle-free, inhaled Technosphere ® Technology. Full Prescribing Information, including BOXED WARNING, Instructions for Use, and Medication Guide can be accessed at afrezza.com.. learn moreNEWS & EVENTS
Conference Call to Begin Today at 5:00 PM ET 1Q 2021 Total Revenues of $17.4 million ; +7% vs. 1Q 2020 Received $230.0 million gross proceeds from 2.5% sen WESTLAKE VILLAGE, Calif. , May 11, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercializatio CAREERS - MANNKIND CORPORATION Thrive with MannKind. Our Total Rewards employee benefits package includes a competitive salary and comprehensive benefits, helping you live the life you want. And, every MannKind employee is eligible for one of our bonus plans and our annual equity program, because our success wouldn’t be possible without the dedication of our people.INVESTOR HOME
Computershare. 462 South 4th Street Suite 1600 Louisville, KY 40202 Phone: +1 877 484 5051 PIPELINE - MANNKIND CORPORATIONNON UNION PIPELINE JOBSPLAINS ALL AMERICAN PIPELINE PROJECTS MannKind sources critical raw materials from suppliers in the United States and Europe and we remain in close communication with key suppliers to assure a reliable supply of insulin. Our US manufacturing facility is fully operational and we are taking a number of steps to prevent any impact to our supplies. ABOUT MANNKIND CORPORATION'S TEAM Michael Castagna, PharmD Chief Executive Officer. Michael is a dedicated leader who is focused on developing a great team at MannKind. A team whose members all know there’s a difference between just managing and truly living with a condition—and who are driven to develop the products and therapies that can help people take control of their health and experience the best of what life has to APRIL 2021 INVESTOR UPDATE April 2021 investor update Our fourth quarter of 2020 produced exceptional results and I’m proud of our growth to start 2021. We continued to work with United PARTNERING - MANNKIND CORPORATION An ultra rapid-acting, inhaled insulin, Afrezza ® offers glucose management in the moment for adults living with type 1 or type 2 diabetes. Now, we’re working to offer Afrezza ® to more people globally. We currently have partnerships in Brazil and India; for commercial opportunities in other regions, contact bd@mannkindcorp.com. 2021 ANNUAL MEETING OF STOCKHOLDERS Event Details. Title. 2021 Annual Meeting of Stockholders. Date and Time. 05/20/21 8:00 AM PDT. Supporting Materials. Supporting Materials. View Presentation. 1.2 MB. PATIENTS - MANNKIND CORPORATION Afrezza ® (insulin human) Inhalation Powder. Learn about our treatment option for patients with type 1 and type 2 diabetes, utilizing our needle-free, inhaled Technosphere ® Technology. Full Prescribing Information, including BOXED WARNING, Instructions for Use, and Medication Guide can be accessed at afrezza.com.. learn more ABOUT MANNKIND'S MISSION At MannKind, our Values serve as the foundation of our culture. Inspired by our employees, they embody the spirit and drive of our founder Alfred Mann, and reflect how we aspire to drive our business forward. They define who we are, how we act, and guide our interactions every day—both with each other and the customers weserve.
PUBLICATIONS
Med. 2020; 37: 752–759. view publication. Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study. Diabetes Technol. Ther. 2018; 20 (10): 639-647. viewpublication.
CONTACT - MANNKIND CORPORATION With the spread of the coronavirus, many individuals are concerned about access to their medication supply. At this time, MannKind does not anticipate that the supply of its inhalable insulin Afrezza ® (insulin human) Inhalation Powder will be affected by the coronavirus.. We will continue to closely monitor our supply chain for potential impact to the supply of Afrezza.CORONAVIRUS UPDATE
With the spread of the coronavirus, many individuals are concerned about access to their medication supply. At this time, MannKind does not anticipate that the supply of its inhalable insulin Afrezza ® (insulin human) Inhalation Powder will be affected by the coronavirus.. We will continue to closely monitor our supply chain for potential impact to the supply of Afrezza. CORPORATE GOVERNANCE Corporate Governance. The Board of Directors of MannKind Corporation (the “Company”) sets high standards for the Company’s employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and tooversee
ANNUAL REPORTS
MannKind Corporation 30930 Russell Ranch Road, Suite 300 Westlake Village, CA 91362 USA EVENTS & PRESENTATIONS MannKind Corporation First Quarter 2021 Earnings Call. 03/17/21. 1:50PM EDT.
OWNERSHIP PROFILE
The Investor Relations website contains information about MannKind Corporation's business for stockholders, potential investors, andfinancial analysts.
MANNKIND ANNOUNCES PRICING OF $40 MILLION PUBLIC OFFERING MannKind Announces Pricing of $40 Million Public Offering. 12/19/18. PDF Version. WESTLAKE VILLAGE, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) ( MannKind) today announced the pricing of an underwritten public offering of 26,666,667 shares of its common stock and warrants to purchase up to an aggregate of* what we do
partnering pipelinepatients
* who we are
about team
news & events
investors
careers
contact
* Afrezza.com
* 818.661.5000
* Menu
* __
*
__
THIS IS LIFE MORE HUMANN.SM Drawing on the legacy of innovator and humanitarian Alfred E. Mann, our team of passionate scientists, researchers, and professionals develops cutting-edge therapeutic products and technologies that help people take control of their health and live—fully humann.about us
PARTNERING
Leveraging our breakthrough therapies and technologies, we can help people get the most out of life—together.what we offer
PIPELINE
Our research and development pipeline is full of potential pathways to a world without limit for all. explore our pipelinePATIENTS
Learn about our treatment option for patients with type 1 and type 2 diabetes, utilizing our needle-free, inhaled Technosphere® Technology, and the support we offer for patients with a prescription. Full Prescribing Information, including BOXED WARNING, Instructions for Use, and Medication Guide can be accessed at afrezza.com.
support options discover afrezza®NEWS & EVENTS
view all news
PreviousNext
{"links":{"self":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/News","first":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/News?page=1","next":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/News?page=2","prev":null,"last":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/News?page=4"},"meta":{"executionDate":"2020-05-10T09:18:06","cmsDomain":"http://investors.mannkindcorp.com","count":100},"data":,"error":null}May 6, 2020
MANNKIND CORPORATION REPORTS 2020 FIRST QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 5:00 PM ET 1Q 2020 Afrezza Net Revenue of $8.0 million ; +58% vs. 1Q 2019 1Q 2020 Afrezza gross profit 48% vs. 21% in 1Q ...read more
April 29, 2020
MANNKIND CORPORATION TO HOLD 2020 FIRST QUARTER FINANCIAL RESULTS CONFERENCE CALL ON MAY 6, 2020 WESTLAKE VILLAGE, Calif. , April 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 first quarter financial results and ...read more
April 15, 2020
MANNKIND RECEIVES FORGIVABLE LOAN UNDER THE PAYCHECK PROTECTIONPROGRAM
Investor call today at 4:30 pm ET to discuss operational update and cost-saving measures being implemented $4.9 million forgivable loan received Pay tempor...read more
March 24, 2020
JENNIFER GRANCIO APPOINTED TO MANNKIND BOARD OF DIRECTORS WESTLAKE VILLAGE, Calif. , March 24, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Jennifer Grancio hasbeen appointed t...
read more
March 17, 2020
MANNKIND REFOCUSES PIPELINE RESOURCES IN RESPONSE TO COVID-19 PANDEMIC WESTLAKE VILLAGE, Calif. , March 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) , a company focused on the development and commercializa...read more
INVESTORS
Our therapeutic innovations are empowering people to take control of their health and get the most out of life. investor information -------------------------CAREERS
Work with passion, with purpose, with people on a mission to make the world a little more humann for all.life at MannKind
MAKE A HUMANN CONNECTION WITH US. REACH OUT ANYTIME. SIGN UP FOR EMAIL UPDATES MannKind Corporation 30930 Russell Ranch Road, Suite 300 Westlake Village, CA 91362 USA contact@mannkindcorp.com818.661.5000
contact@mannkindcorp.com818.661.5000
SIGN UP FOR EMAIL UPDATES EMAIL SUBSCRIBE FORMEmail Address
Terms of Use Privacy PolicyPatent Notices
Corporate Governance__ __
__
__
2020 MannKind Corporation. All rights reserved.Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0